Search

Displaying results 4651 - 4660 of 10000 in total
  1. Drug

    OSI-930

    go.drugbank.com/drugs/DB05913
    Investigational

    OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. … OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2).

  2. Drug

    Tetraethylammonium

    go.drugbank.com/drugs/DB08837
    Investigational

    The most common use of tetraethylammonium presently is as a pharmacological research agent that blocks selective potassium channels. … As an experimental agent, tetraethylammonium is used in its salt forms such as tetraethylammonium chloride and tetraethylammonium bromide.

  3. Drug

    CTS-21166

    go.drugbank.com/drugs/DB06073
    Investigational

    CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. … CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far.

  4. Drug

    LS11

    go.drugbank.com/drugs/DB05918
    Investigational

    It is used to treat many kinds of cancers. … LS11(talaporfin sodium) is an agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity.

  5. Drug

    MDX-1303

    go.drugbank.com/drugs/DB05945
    Investigational

    toxins known as the anthrax protective antigen. … MDX-1303 is a fully human antibody against the inhalation anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium, and targets a protein component of these lethal

  6. Drug

    99mTc-14 F7 Mab

    go.drugbank.com/drugs/DB05867
    Experimental

    Growth inhibition and prolonged survival of the myeloma tumor were obtained as evidences of anti tumor effect after treatment with 99mTc 14F7 Mab.

  7. Drug

    Apadenoson

    go.drugbank.com/drugs/DB05009
    Investigational

    Apadenoson is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies. … It is developed by Bristol-Myers Squibb and is in phase II of clinical trials.

  8. Drug

    Lunacalcipol

    go.drugbank.com/drugs/DB05024
    Investigational

    Cytochroma anticipates that CTA018 will be more potent than currently marketed vitamin D analogues such as calcitriol and calcipotriol and it is expected to have a greater safety index. … Preclinical studies have shown that CTA018 inhibits the proliferation of rapidly dividing cells such as human epidermal keratinocytes (skin cells) and is also effective in inhibiting pro-inflammatory cytokine

  9. Drug

    UCB-1184197

    go.drugbank.com/drugs/DB05092
    Investigational

    Sclerosis (MS). … (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis.

  10. Drug

    AX200

    go.drugbank.com/drugs/DB05093
    Investigational

    AX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval. … And this is where the double neurotherapeutic approach is most beneficial: AX200 stops neuronal cell death in the acute phase of stroke, while stimulating simultaneously the regeneration of nervous tissue